Dr Gareth Ambler

* @ucl.ac.uk

Biographical Details

Gareth is an Associate Professor in Medical Statistics at the Department of Statistical Science, UCL and a member of the Biostatistics Group within the Research Support Centre. Gareth completed a PhD in Statistics in 1996 at the University of Sussex. Previously he worked in the department of Medical Statistics at Imperial College School of Medicine. 

• Biostatistics Group within the Research Support Centre

Other Affiliations

• Member of the Editorial Board, BMC Diagnostic and Prognostic Research (2016-)
• Member of the Editorial Board, Colorectal Disease (2012-)
• Scientific Director, UCL Surgical and Interventional Trials Unit
• Member of the NIHR RfPB London Regional Funding Committee (2012-2016)
• Member of the UCLH BRC/CRDC Funding Committee (2011-)

Research Interests

• Risk prediction models
• Survival data
• Clinical trials
• Hierarchical models
• Missing data

Teaching

• Medical Statistics 1 (STAT0014)
• Medical Statistics 2 (STAT0015)
• Statistical Methods in Research (MEDC0046)

Publications

• Publications can be found on IRIS.

Selected Recent Grants

• Guidance On Sample Size When Using Observational Data To Develop And Validate Risk Prediction Models In Health Research. PI: Gareth Ambler (UCL). MRC. £317,135. 1/12/17 (36 months).
• Clinical and cost effectiveness of a parent mediated intervention to reduce challenging behaviour in pre-schoolers with moderate to severe learning disability: a randomised controlled trial. PI: Angela Hassiotis (UCL). NIHR HTA. £1,405,282. 1/6/17 (48 months).
• Does Laryngeal Reinnervation for Type I Thyroplasty give better voice results for patients with Unilateral Vocal Fold Paralysis (VOCALIST): a feasibility study? PI: Martin Birchall (UCL). NIHR RfPB. £350,000. 1/4/15 (24 months).
• Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes. PI: Davor Jurkovic. NIHR HS&DR. £839,132. 1/11/15 (24 months).
• NEST: Detecting Ictogenicity And Epileptogenesis. PI: Matthias Koepp (UCL). MRC. £1,340,320. 1/4/14 (60 months).
• An investigation into the use of shrinkage methods to alleviate the over-fitting of prognostic models with few events for independent and clustered data. PI: Rumana Omar (UCL). MRC. £300,445. 1/2/13 (36 months).
• Does vascular endothelial growth factor gene therapy safely improve outcome in severe early-onset fetal growth restriction? PI: Anna David (UCL). EU FP7. 6M euros. 1/2/13 (72 months).
• Low-dose Intravenous Immunoglobulin Treatment for Complex Regional Pain Syndrome (‘LIPS’) randomised controlled trial.. PI: Dr Andreas Goebel (Liverpool University). National Institute of Health Research Efficacy and Mechanism Evaluation (NIHR EME). £647,645. 1/6/12 (48 months).
• Health-Related Quality of Life in two treatment pathways for primary open angle glaucoma and ocular hypertension: a randomised controlled trial of initial selective laser trabeculoplasty versus conventional medical therapy. PI: Dr Gus Gazzard (Institute of Ophthalmology). National Institute of Health Research Health Technology Assessment (NIHR HTA). £1,692,821. 1/9/12 (72 months).
• Optimising team functioning, preventing relapse and enhancing recovery in crisis resolution teams: the CORE programme (CRT Optimisation and RElapse prevention). PI: Dr Sonia Johnson (UCL). National Institute of Health Research Programme Grant. £1,993,527. 1/10/11 (60 months).
• EACH study: Evaluation of Array Comparative genomic Hybridisation in prenatal diagnosis of fetal anomalies.PI: Dr Steve Robson. NIHR EME. £1,558,235. 1/11/11 (36 months).
• The effect of neo-adjuvant chemotherapy on exercise capacity and outcome following upper gastrointestinal cancer surgery.PI: Mike Grocott. NIHR RfPB. £250,000. 4/8/11 (36 months).